Obesity

Semaglutide was associated with improved HF symptoms and exercise capacity and reduced body weight and inflammation among patients with obesity across the range of HF with mildly reduced and preserved ejection fraction, a speaker reported.

Study data suggest that children and adolescents with a high polygenic risk score for polycystic ovary syndrome tend to have a higher BMI and are more likely to develop obesity.

With its impact on individuals and society, addressing obesity requires a multidisciplinary approach that combines medical expertise, research and public health initiatives.

DALLAS — Older adults who received anti-obesity medications lost a similar amount of weight at 3 to 5 years as younger adults, with no increased side effects, according to research presented at ObesityWeek.

GE HealthCare announced it received FDA 510(k) clearance of its next-generation image-guided system, designed to optimize imaging at the right dose regardless of patient size, for use during interventional CV procedures.

DALLAS — In this Healio video exclusive, Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS, discusses cultural competency with regard to obesity care.

The 2023 Cardiometabolic Health Congress will return in-person to Boston with the latest updates spanning all aspects of cardiometabolic health, including CVD, diabetes, kidney disease, lipid and lifestyle management and obesity.

DALLAS — In this Healio video exclusive, Marshall Chin, MD, MPH, discussed the importance of measuring sex, gender identity and sexual orientation for advancing health equity.

DALLAS — Weight loss with the triple-hormone agonist retatrutide varies by sex, age and baseline BMI, according to a speaker.

DALLAS — Adults with obesity who received tirzepatide for 72 weeks following a 12-week intensive lifestyle intervention achieved a total mean weight loss greater than 24%, according to data from the SURMOUNT-3 trial.